Last Updated : March 11, 2025
Details
FilesGeneric Name:
pembrolizumab
Project Status:
Active
Therapeutic Area:
Advanced or recurrent endometrial carcinoma
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0383-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Keytruda is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, in combination with carboplatin and paclitaxel and then continued as monotherapy.
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Indications:
Keytruda is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, in combination with carboplatin and paclitaxel and then continued as monotherapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 04-Oct-24 |
|---|---|
| Call for patient/clinician input closed | 02-Dec-24 |
| Submission received | 14-Nov-24 |
| Submission accepted | 28-Nov-24 |
| Review initiated | 29-Nov-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 21-Feb-25 |
| Deadline for sponsors comments | 04-Mar-25 |
| CADTH review report(s) and responses to comments provided to sponsor | 28-Mar-25 |
| Expert committee meeting (initial) | 09-Apr-25 |
| Draft recommendation issued to sponsor | April 23, 2025 To April 25, 2025 |
| Draft recommendation posted for stakeholder feedback | 01-May-25 |
| End of feedback period | 15-May-25 |
Files
Last Updated : March 11, 2025